Changing Course in Pancreatic Cancer

Small, yet significant, advances are reshaping pancreatic cancer treatment.

Talk about this article with other patients, caregivers, and advocates in the Pancreatic CURE discussion group.
Susan Smith is hopeful. For the first time in years, a new drug combination has put her pancreatic cancer back into remission. In May, she began receiving gemcitabine in combination with Abraxane (nab-paclitaxel), a drug already approved by the Food and Drug Administration (FDA) for treating breast and lung cancers. A recent scan showed very encouraging news—the size of the lesion was reduced by nearly half. “Both my doctor and I were extremely pleased with the results,” Smith says.

The 66-year-old resident of Vero Beach, Fla., received her pancreatic cancer diagnosis almost seven years ago and underwent surgery to remove part of her pancreas and spleen. She then received an intense regimen of chemotherapy and radiation and was followed closely by her oncologist for the next five years without further treatment, as she appeared to be in remission.

Five years after receiving her diagnosis, she no longer needed imaging scans. However, in March, Smith began experiencing back pain. Scans and a biopsy revealed that her cancer had metastasized to her liver.

Her initial treatment with Abraxane had to be halted because it made her white blood cell count plummet. She restarted treatment with an altered schedule that included doses of granulocyte colony-stimulating factors (G-CSFs) to boost her white blood cells.

Early on, Smith struggled with other side effects, including rash, thrush, mouth sores and poor appetite. But as the treatment progressed, the side effects lessened. “Now I experience tiredness, lethargy and flu-like symptoms on the third and fourth day after chemo, but other than that I get along well,” she says.

Early Detection is Important

About 45,000 new cases of pancreatic cancer are estimated to be diagnosed this year in the U.S. Patients with the disease face a tough challenge due to its aggressive nature and resistance to available treatments. Moreover, it can be difficult to diagnose in its early stages (less than 20 percent of tumors are confined to the pancreas at the time of diagnosis), so all too often, the disease has already spread to the point where surgical removal of the tumor is not possible. Thus, the one-year survival rate for all stages of the disease combined is about 20 percent. Unfortunately, disease recurrence is common, and the five-year survival rate for pancreatic cancer is 6 percent.

The best predictors of long-term survival following surgery (considered the only potentially curative treatment at this time) are small tumor size, no lymph node involvement and no cancer cells surrounding the tissue where the tumor was removed. There is also increasing evidence that the best outcomes after surgery for the disease are achieved at major medical centers that perform more than 20 pancreatic surgeries annually.

Inroads into effective treatments and better diagnostics have been slower than with many other cancers, but new approaches are emerging, especially as more is learned about the biologic makeup of the disease.

Talk about this article with other patients, caregivers, and advocates in the Pancreatic CURE discussion group.
Special Feature
Share Your Art
Related Articles
Considerations When Monitoring Nutritional Status
In this segment, Rachel Wong highlights the most common markers she monitors when assessing the progression of a patient's nutritional status. She also discusses what patients may expect in terms of side effects following radiation therapy and provides suggestions for managing a diet when experiencing a lack of appetite or fatigue.
Survival Benefit With Onivyde Sustained in Updated Pancreatic Cancer Study Data
This study of Onivyde, 5-FU and leucovorin for the treatment of patients with metastatic pancreatic cancer was presented at the 2016 Gastrointestinal Cancers Symposium.
Initial Considerations Upon a Diagnosis
Dr John Marshall explains the importance of receiving support from loved ones when coping with a diagnosis of cancer and remarks that it is vital to recognize that cancer affects everyone who is part of a patient’s life. Donald Wilson briefly discusses his diagnosis of pancreatic cancer and what it was like to hear the news.
Related Videos
Julie Fleshman on the Role of Nutrition in the Life of a Patient With Pancreatic Cancer
Julie Fleshman, JD, MBA, president, CEO, Pancreatic Cancer Action Network, discusses the role of nutrition in the life of a patient with pancreatic cancer.
Michael Ferraro on His Mother's Pancreatic Cancer Journey
Michael Ferraro, executive chef, Delicatessen, discusses his mother's journey with pancreatic cancer and his role in the Cooking. Comfort. Care. Nourishment for the Pancreatic Cancer Fight program.
Lifestyle Recommendations for Newly Diagnosed Pancreatic Cancer Patients
Min Li, of the University of Texas Health Sciences Health Science Center in Houston, offers dietary and lifestyle suggestions for newly diagnosed pancreatic cancer patients.